| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
β-amyloid Peptides and Amyloid Plaques in Alzheimer’s Disease
|
Gouras, Gunnar K.
|
|
2014
|
12 |
1 |
p. 3-11
|
artikel
|
| 2 |
β-amyloid Peptides and Amyloid Plaques in Alzheimer's Disease
|
Gouras, Gunnar K.
|
|
|
12 |
1 |
p. 3-11
|
artikel
|
| 3 |
A Novel Method for Inducing Nerve Growth via Modulation of Host Resting Potential: Gap Junction-Mediated and Serotonergic Signaling Mechanisms
|
Blackiston, Douglas J.
|
|
2014
|
12 |
1 |
p. 170-184
|
artikel
|
| 4 |
A Novel Method for Inducing Nerve Growth via Modulation of Host Resting Potential: Gap Junction-Mediated and Serotonergic Signaling Mechanisms
|
Blackiston, Douglas J.
|
|
|
12 |
1 |
p. 170-184
|
artikel
|
| 5 |
A Systems Approach to Drug Discovery in Alzheimer’s Disease
|
Shelanski, Michael
|
|
2015
|
12 |
1 |
p. 126-131
|
artikel
|
| 6 |
A Systems Approach to Drug Discovery in Alzheimer's Disease
|
Shelanski, Michael
|
|
|
12 |
1 |
p. 126-131
|
artikel
|
| 7 |
Biometals and Their Therapeutic Implications in Alzheimer’s Disease
|
Ayton, Scott
|
|
2014
|
12 |
1 |
p. 109-120
|
artikel
|
| 8 |
Biometals and Their Therapeutic Implications in Alzheimer's Disease
|
Ayton, Scott
|
|
|
12 |
1 |
p. 109-120
|
artikel
|
| 9 |
Caspases: Therapeutic Targets in Neurologic Disease
|
Troy, Carol M.
|
|
2014
|
12 |
1 |
p. 42-48
|
artikel
|
| 10 |
Caspases: Therapeutic Targets in Neurologic Disease
|
Troy, Carol M.
|
|
|
12 |
1 |
p. 42-48
|
artikel
|
| 11 |
Chronic Neurodegeneration After Traumatic Brain Injury: Alzheimer Disease, Chronic Traumatic Encephalopathy, or Persistent Neuroinflammation?
|
Faden, Alan I.
|
|
2014
|
12 |
1 |
p. 143-150
|
artikel
|
| 12 |
Chronic Neurodegeneration After Traumatic Brain Injury: Alzheimer Disease, Chronic Traumatic Encephalopathy, or Persistent Neuroinflammation?
|
Faden, Alan I.
|
|
|
12 |
1 |
p. 143-150
|
artikel
|
| 13 |
Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology
|
Cedarbaum, Jesse M.
|
|
2014
|
12 |
1 |
p. 151-169
|
artikel
|
| 14 |
Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology
|
Cedarbaum, Jesse M.
|
|
|
12 |
1 |
p. 151-169
|
artikel
|
| 15 |
Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats
|
Citraro, Rita
|
|
2014
|
12 |
1 |
p. 250-262
|
artikel
|
| 16 |
Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats
|
Citraro, Rita
|
|
|
12 |
1 |
p. 250-262
|
artikel
|
| 17 |
Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer’s Disease
|
Kim, Tae-Wan
|
|
2014
|
12 |
1 |
p. 132-142
|
artikel
|
| 18 |
Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease
|
Kim, Tae-Wan
|
|
|
12 |
1 |
p. 132-142
|
artikel
|
| 19 |
Early-Stage Treatment with Withaferin A Reduces Levels of Misfolded Superoxide Dismutase 1 and Extends Lifespan in a Mouse Model of Amyotrophic Lateral Sclerosis
|
Patel, Priyanka
|
|
2014
|
12 |
1 |
p. 217-233
|
artikel
|
| 20 |
Early-Stage Treatment with Withaferin A Reduces Levels of Misfolded Superoxide Dismutase 1 and Extends Lifespan in a Mouse Model of Amyotrophic Lateral Sclerosis
|
Patel, Priyanka
|
|
|
12 |
1 |
p. 217-233
|
artikel
|
| 21 |
Eighth Annual Huntington Disease Clinical Research Symposium
|
|
|
2014
|
12 |
1 |
p. 263-284
|
artikel
|
| 22 |
Eighth Annual Huntington Disease Clinical Research Symposium
|
|
|
|
12 |
1 |
p. 263-284
|
artikel
|
| 23 |
Erratum to: Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology
|
Cedarbaum, Jesse M.
|
|
2014
|
12 |
1 |
p. 285
|
artikel
|
| 24 |
Erratum to: Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology
|
Cedarbaum, Jesse M.
|
|
|
12 |
1 |
p. 285
|
artikel
|
| 25 |
Interaction of Paroxetine with Mitochondrial Proteins Mediates Neuroprotection
|
Steiner, Joseph P.
|
|
2014
|
12 |
1 |
p. 200-216
|
artikel
|
| 26 |
Interaction of Paroxetine with Mitochondrial Proteins Mediates Neuroprotection
|
Steiner, Joseph P.
|
|
|
12 |
1 |
p. 200-216
|
artikel
|
| 27 |
Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice
|
Valdeolivas, Sara
|
|
2014
|
12 |
1 |
p. 185-199
|
artikel
|
| 28 |
Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice
|
Valdeolivas, Sara
|
|
|
12 |
1 |
p. 185-199
|
artikel
|
| 29 |
Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer’s Disease
|
Gurney, Mark E.
|
|
2014
|
12 |
1 |
p. 49-56
|
artikel
|
| 30 |
Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer's Disease
|
Gurney, Mark E.
|
|
|
12 |
1 |
p. 49-56
|
artikel
|
| 31 |
Probing the Secrets of Alzheimer’s Disease Using Human-induced Pluripotent Stem Cell Technology
|
Goldstein, Lawrence S. B.
|
|
2014
|
12 |
1 |
p. 121-125
|
artikel
|
| 32 |
Probing the Secrets of Alzheimer's Disease Using Human-induced Pluripotent Stem Cell Technology
|
Goldstein, Lawrence S.B.
|
|
|
12 |
1 |
p. 121-125
|
artikel
|
| 33 |
Promoting Autophagic Clearance: Viable Therapeutic Targets in Alzheimer’s Disease
|
Friedman, Lauren G.
|
|
2014
|
12 |
1 |
p. 94-108
|
artikel
|
| 34 |
Promoting Autophagic Clearance: Viable Therapeutic Targets in Alzheimer's Disease
|
Friedman, Lauren G.
|
|
|
12 |
1 |
p. 94-108
|
artikel
|
| 35 |
Reversing Synapse Loss in Alzheimer’s Disease: Rho-Guanosine Triphosphatases and Insights from Other Brain Disorders
|
Lefort, Roger
|
|
2015
|
12 |
1 |
p. 19-28
|
artikel
|
| 36 |
Reversing Synapse Loss in Alzheimer's Disease: Rho-Guanosine Triphosphatases and Insights from Other Brain Disorders
|
Lefort, Roger
|
|
|
12 |
1 |
p. 19-28
|
artikel
|
| 37 |
Stuck in the Mire
|
Shelanski, Michael
|
|
2015
|
12 |
1 |
p. 1-2
|
artikel
|
| 38 |
Stuck in the Mire
|
Shelanski, Michael
|
|
|
12 |
1 |
p. 1-2
|
artikel
|
| 39 |
Synaptic Therapy in Alzheimer’s Disease: A CREB-centric Approach
|
Teich, Andrew F.
|
|
2015
|
12 |
1 |
p. 29-41
|
artikel
|
| 40 |
Synaptic Therapy in Alzheimer's Disease: A CREB-centric Approach
|
Teich, Andrew F.
|
|
|
12 |
1 |
p. 29-41
|
artikel
|
| 41 |
Targeting Axonal Protein Synthesis in Neuroregeneration and Degeneration
|
Baleriola, Jimena
|
|
2014
|
12 |
1 |
p. 57-65
|
artikel
|
| 42 |
Targeting Axonal Protein Synthesis in Neuroregeneration and Degeneration
|
Baleriola, Jimena
|
|
|
12 |
1 |
p. 57-65
|
artikel
|
| 43 |
Targeting the Prodromal Stage of Alzheimer’s Disease: Bioenergetic and Mitochondrial Opportunities
|
Caldwell, Charles C.
|
|
2014
|
12 |
1 |
p. 66-80
|
artikel
|
| 44 |
Targeting the Prodromal Stage of Alzheimer's Disease: Bioenergetic and Mitochondrial Opportunities
|
Caldwell, Charles C.
|
|
|
12 |
1 |
p. 66-80
|
artikel
|
| 45 |
The Evolving Biology of Microglia in Alzheimer’s Disease
|
Malm, Tarja M.
|
|
2014
|
12 |
1 |
p. 81-93
|
artikel
|
| 46 |
The Evolving Biology of Microglia in Alzheimer's Disease
|
Malm, Tarja M.
|
|
|
12 |
1 |
p. 81-93
|
artikel
|
| 47 |
The Riluzole Derivative 2-Amino-6-trifluoromethylthio-benzothiazole (SKA-19), a Mixed KCa2 Activator and NaV Blocker, is a Potent Novel Anticonvulsant
|
Coleman, Nichole
|
|
2014
|
12 |
1 |
p. 234-249
|
artikel
|
| 48 |
The Riluzole Derivative 2-Amino-6-trifluoromethylthio-benzothiazole (SKA-19), a Mixed KCa2 Activator and NaV Blocker, is a Potent Novel Anticonvulsant
|
Coleman, Nichole
|
|
|
12 |
1 |
p. 234-249
|
artikel
|
| 49 |
The Use of Pharmacological Retromer Chaperones in Alzheimer’s Disease and other Endosomal-related Disorders
|
Berman, Diego E.
|
|
2014
|
12 |
1 |
p. 12-18
|
artikel
|
| 50 |
The Use of Pharmacological Retromer Chaperones in Alzheimer's Disease and other Endosomal-related Disorders
|
Berman, Diego E.
|
|
|
12 |
1 |
p. 12-18
|
artikel
|
Tijdschrift beschrijving